HealthdirectFree Australian health advice you can count on.

( ARTG ) For the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus.​‍​​​​​‍​‍‍‍‍​‍‍ For prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estalis Continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.